Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Double Blind Phase III Trial Comparing Safety and Efficacy of Bevacizumab (Mabscale LLC, Russia) + Paclitaxel + Carboplatin to Avastin® + Paclitaxel + Carboplatin in Inoperable or Advanced Non-squamous Non-small-cell Lung Cancer

NCT05654454 is registered in ClinicalTrials.gov with Mabscale, LLC as lead sponsor.

NCT NCT05654454
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05654454 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Double Blind Phase III Trial Comparing Safety and Efficacy of Bevacizumab (Mabscale LLC, Russia) + Paclitaxel + Carboplatin to Avastin® + Paclitaxel + Carboplatin in Inoperable or Advanced Non-squamous Non-small-cell Lung Cancer
Lead sponsor
Mabscale, LLC
Phase
Phase 3
Overall status
Recruiting
Start date
May 31, 2023
Completion date
March 31, 2027
Enrollment
620 (estimated)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer